N-Terminal Pro-B-Type Natriuretic Peptide
Other marker
NT-proBNP
N-Terminal Pro-B-Type Natriuretic Peptide
Cardiac biomarker released from cardiomyocytes in response to myocardial wall stress. Highly sensitive for detecting heart failure, left ventricular hypertrophy, and cardiac dysfunction.
PED Notes
Critical marker for AAS users. AAS cause concentric left ventricular hypertrophy — thickening of the heart wall from chronic hypertension and direct androgen receptor stimulation in cardiac tissue. The HAARLEM study showed 4.9% decline in LV ejection fraction after a 16-week cycle. 58% of AAS users show cardiac remodelling on echo. Trenbolone (BP elevation, severe lipid disruption), boldenone (erythrocytosis increasing cardiac workload), and GH+insulin (cardiomegaly) are the most concerning compounds. Always draw after 48+ hours of rest — intense training transiently elevates NT-proBNP.
When elevated (>125 ng/L at rest in males <50):
Immediate actions:
- Retest after 72 hours of complete rest to rule out exercise-induced transient elevation
- If persistently elevated: obtain echocardiogram (LV wall thickness, ejection fraction, diastolic function, global longitudinal strain)
- Check kidney function — reduced eGFR elevates NT-proBNP clearance time
- If >300 ng/L: cardiology referral is mandatory
Supplements (cardioprotective — do NOT replace medical evaluation):
- CoQ10 (Ubiquinol) -- 200-400mg/day: Improves mitochondrial energy production in cardiomyocytes, reduces oxidative stress
- Omega-3 (EPA/DHA) -- 4g/day: Anti-arrhythmic, anti-inflammatory, reduces blood pressure
- Magnesium (Taurate or Glycinate) -- 400-600mg/day: Antiarrhythmic, vasodilatory
- Taurine -- 3-5g/day: Cardioprotective, antiarrhythmic, reduces blood pressure
Lifestyle:
- Monitor blood pressure: target <130/80 mmHg — AAS-induced hypertension drives LVH
- Control haematocrit (<52%): high viscosity increases cardiac workload
- Regular cardiovascular exercise (150 min/week moderate-intensity)
- Consider annual echocardiography while using AAS
- If persistently >125 ng/L, strongly consider reducing to TRT doses
- Manage lipids aggressively
References:
- Baggish, A. L., Weiner, R. B., Kanayama, G., et al. (2017). Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation, 135(21), 1991-2002. DOI: 10.1161/CIRCULATIONAHA.116.026945
- Smit, D. L., Honber, J. K. G., den Heijer, M., & de Ronde, W. (2022). Anabolic androgenic steroids induce reversible left ventricular hypertrophy and cardiac dysfunction (HAARLEM study). Frontiers in Reproductive Health, 4, 1008455. DOI: 10.3389/frph.2022.1008455
- Jankowska, E. A., Tkaczyszyn, M., Suchocki, T., et al. (2022). Reference ranges for NT-proBNP in a large general population cohort. Circulation: Heart Failure, 15(10), e009427. DOI: 10.1161/CIRCHEARTFAILURE.121.009427
History Chart
Reading History
Frequently Asked Questions
Reference Ranges
Standard Range
VitalMetrics Range